Value of contrast ultrasonography in the detection of significant prostate cancer: Correlation with radical prostatectomy specimens

Prostate

Volumn 53, Issue 3, 2002, Pages 246-253

  Sedelaar, J P M ^a   Van Leenders, G J L H ^a   Goossen, T E B ^a   Hulsbergen van Der Kaa, C A ^a   Van Adrichem, N P ^b   Wijkstra, H ^a   De La Rosette, J J M C H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EEMLAND HOSPITAL   (Netherlands)

Author keywords

3D ultrasonography imaging; Contrast ultrasonography; Histology; Imaging; Prostate cancer

Indexed keywords

ARTICLE; CANCER STAGING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER ECHOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; THREE DIMENSIONAL IMAGING;

ADENOCARCINOMA; AGED; CONTRAST MEDIA; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; PROSTATECTOMY; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, DOPPLER;

EID: 0036843090     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10145     Document Type: Article

References (22)

1. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000;50:34-49.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-552.
3. Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control 1998;9:519-527.
4. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1679-1684.
5. Sedelaar JPM, van Leenders GJLH, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JAWM, Debruyne FMJ, Wijkstra H, de la Rosette JJMCH. Microvessel density: Correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001;40:285-293.
6. Sedelaar JPM, Goossen TEB, Wijkstra H, de la Rosette JJMCH. Reproducibility of contrast ultrasonography of the prostate. Ultrasound Med Biol 2001;27:595-602.
7. Unal D, Sedelaar JPM, Aarnink RG, van Leenders GJLH, Wijkstra H, Debruyne FMJ, de la Rosette JJMCH. Three-dimensional contrast-enhanced power Doppler ultrasonography and conventional examination methods: The value of diagnostic predictors of prostate cancer. BJU Int 2000;86:58-64.
8. Bogers HA, Sedelaar JPM, Beerlage HP, de la Rosette JJMCH, Debruyne FMJ, Wijkstra H, Aarnink RG. Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: Correlation with biopsy outcome. Urology 1999;54:97-104.
9. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-1451.
10. Ruijter ET, Miller GJ, Aalders TW, van de Kaa CA, Schalken JA, Debruyne FM, Boon ME. Microwave-stimulated fixation of entire prostatectomy specimen. J Pathol 1997;183:364-375.
11. Blomley MJ, Cosgrove DO, Jayaram V, Eckersley R, Albrecht T, DeSouza NM. Quantitation of enhanced transrectal ultrasound of the prostate: Work in progress. Radiology 1997;205:598-599.
12. Cosgrove DO, Kiely P, Williamson R, Blomley MJ, Eckersley RJ. Ultrasonographic contrast media in the urinary tract. BJU Int 2000;86:7-11.
13. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-938.
14. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-294.
15. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: Value of systematic biopsies. J Urol 1996;156:1059-1063.
16. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: Characteristics and clinical relevance in 100 radical prostatectomy specimens - A different view. J Urol 1997;157:244-250.
17. Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, Sesterhenn IA. Prostate-specific antigen-detected prostate cancer (stage T1c): An analysis of whole-mount prostatectomy specimens. Prostate 1997;32:59-64.
18. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160:2407-2411.
19. Hautmann SH, Conrad S, Henke RP, Erbersdobler A, Simon J, Straub M, Graefen M, Hautmann RE, Huland H. Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology. J Urol 2000;163:1734-1738.
20. Brossner C, Bayer G, Madersbacher S, Kuber W, Klingler C, Pycha A. Twelve prostate biopsies detect significant cancer volumes (>0.5 ml). BJU Int 2000;85:705-707.
21. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, Ohori M, Scardino PT. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol 1998;29:856-862.
22. Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: Contrast-enhanced us for detection. Radiology 2001;219:219-225.